SCHEMBL6776545

SCHEMBL6776545

O=C(O)c1ccc(COc2cccnc2)cc1-c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.52
FNTB P49356 1/20 0.52
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
PRKAB2 O43741 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
PRKAG3 Q9UGI9 1/20 0.48
PRKAG2 Q9UGJ0 1/20 0.48
PRKAB1 Q9Y478 1/20 0.48
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SMPD1 P17405 1/20 0.47
IKBKB O14920 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778188 0.89 FNTA (0.54) FNTAFNTBNOS1NOS2MAPT
SCHEMBL6771653 0.86 FNTA (0.66) FNTAFNTB
SCHEMBL6774670 0.85 PRKAB2 (0.58) CYP4F2CYP4A11PRKAB2PRKAG1PRKAA2
SCHEMBL6777255 0.84 KMT2A (0.48) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL6771761 0.83 FNTA (0.49) FNTAFNTBCYP4F2CYP4A11NOS1
SCHEMBL6777219 0.83 FNTA (0.62) FNTAFNTB
SCHEMBL6776152 0.83 FNTA (0.62) FNTAFNTB
SCHEMBL6776797 0.83 CYP4F2 (0.47) FNTAFNTBCYP4F2CYP4A11NOS1
SCHEMBL6776309 0.82 FNTA (0.64) FNTAFNTB
SCHEMBL6776314 0.82 FNTA (0.64) FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US disclosed
EP-0873123-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2003-04-09 EP disclosed
US-20020193596-A1 Inhibitors of protein isoprenyl transferases UNIVERSITY OF PITTSBURGH (US) 2002-12-19 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193596-A1 Inhibitors of protein isoprenyl transferases LANCL1, FNTB, DHCR7 FNTA 20/4885FNTB 2/4885CYP4F2 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.